PT  - JOURNAL ARTICLE
AU  - A.E. Clark
AU  - Z. Wang
AU  - B. Cantarel
AU  - M. Kanchwala
AU  - C. Xing
AU  - L. Chen
AU  - P. Irwin
AU  - Y. Xu
AU  - D. Oliver
AU  - F. Lee
AU  - J.R. Gagan
AU  - L. Filkins
AU  - A. Muthukumar
AU  - J.Y. Park
AU  - R. Sarode
AU  - J.A. SoRelle
TI  - Multiplex Fragment Analysis Identifies SARS-CoV-2 Variants
AID  - 10.1101/2021.04.15.21253747
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.15.21253747
4099  - http://medrxiv.org/content/early/2021/04/16/2021.04.15.21253747.short
4100  - http://medrxiv.org/content/early/2021/04/16/2021.04.15.21253747.full
AB  - The rapid spread of SARS-CoV-2 Variants of Concern (VOC) necessitates systematic efforts for epidemiological surveillance. The current method for identifying variants is viral whole genome sequencing (WGS). Broad clinical adoption of sequencing is limited by costly equipment, bioinformatics support, technical expertise, and time for implementation. Here we describe a scalable, multiplex, non-sequencing-based capillary electrophoresis assay to affordably screen for SARS-CoV-2 VOC.Competing Interest StatementPark is a scientific advisory board member of Miraca Holdings; Baylor Genetics, Fujirebio and SRL Labs are subsidiaries. SoRelle owns stock in Myriad Genetics.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed by the UT Southwestern IRB and it received a Health Surveillance waiver.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request provided it does not interfere with publication in a peer-review journal.